Multi-layer platform coordination for open innovation in oligonucleotide therapeutics.

As technology evolves and medical needs diversify, the pharmaceutical industry must accelerate its openness. This study analysed interorganizational alliances in R&D for the new modality of oligonucleotide therapeutics in order to explore the requirements for establishing new markets. The results confirmed that the market has developed in stages, employing open innovation for different purposes according to technological progress.

Case of Radiation-Induced Angiosarcoma after Breast-Conserving Surgery with Hypofractionated Radiotherapy in a Japanese Patient.

Radiation-induced angiosarcoma (RIAS) is a rare, late adverse event of radiotherapy comprising approximately half of all radiation-induced sarcomas. It has a relatively short latency period and generally unfavorable prognosis. This study presents a case of RIAS that developed 5 years and 11 months after the completion of hypofractionated radiotherapy (42.

Development of a laboratory test using stem cuttings to measure resistance to foot rot disease caused by in sweetpotato.

Over the last several years, foot rot caused by has become the most destructive sweetpotato disease in the southernmost region of Japan. Breeding of cultivars resistant to foot rot is required for effective and low-cost management. Field tests are often used to evaluate resistance of cultivars, but this approach has several limitations, including a long test period of several months and the requirement of field isolation and labor-intensive procedures.

RNA G-quadruplexes and calcium ions synergistically induce Tau phase transition in vitro.

Tau aggregation is a defining feature of neurodegenerative tauopathies, including Alzheimer's disease, corticobasal degeneration, and frontotemporal dementia. This aggregation involves the liquid-liquid phase separation (LLPS) of Tau, followed by its sol-gel phase transition, representing a crucial step in aggregate formation both in vitro and in vivo. However, the precise cofactors influencing Tau phase transition and aggregation under physiological conditions (e.

Open Innovation and Regulatory Challenges in New Modality Development: The Pivotal Role of Contract Development and Manufacturing Organisations in Advancing Antibody Drugs.

Background: Ensuring regulatory-compliant manufacturing capability is an essential challenge for new treatment modalities, but its internalisation is not easy for pharmaceutical companies, especially start-ups. This study examines the functions and requirements of contracted development and manufacturing organisations (CDMOs) using the development process of antibody medicines as a case study.

Methods: Utilizing PubMed, Cortellis and Patent Integration databases, this study delves into publication and contractual trends in monoclonal antibody drugs (mAbs) development, alongside an analysis of patent filings by CDMOs, offering a comprehensive overview of the evolving landscape in mAbs innovation.